Diego A. Díaz-García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
”RET Fusion-Positive LUAD: Fusion partner matters.
In 268 RET+ LUAD cases, KIF5B-RET represented 65% of fusions and was linked to earlier-stage disease. CDKN2A co-mutations were enriched in non-KIF5B tumors.
Selective RET inhibitors achieved ORR 57.9% and mPFS 12.0 months. Non-KIF5B fusions showed longer PFS with pralsetinib vs KIF5B-RET (17.0 vs 5.5 months).
Fusion partners may influence response to RET-targeted therapy.”
Title: RET Fusion–Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy
Authors: Zihan Sun, Tianyi Liu, Jiaxi Xu, Bingzhi Wang, Zuxuan Zhao, Lina Gao, Lei Guo, Weihua Li, Jianming Ying
ASCO Living Guideline 2026.3.0 Updates Treatment Roadmap for Stage IV NSCLC With Driver Alterations
